Should You Buy HealthStream Inc (HSTM) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/29
HSTM is not a good buy right now for a beginner long-term investor who wants to deploy capital immediately. The broader technical setup is still bearish (long-term downtrend via moving averages), insider selling has accelerated, and Wall Street just cut the price target while maintaining a Hold. With no near-term positive catalysts in the news and earnings not until 2026-02-23, risk/reward is unattractive at the current ~$21.75—this is a Hold/avoid-new-buy for now.
Technical Analysis
Price is ~21.75 (flat on the day). Trend is still bearish: SMA_200 > SMA_20 > SMA_5 indicates the stock remains in a longer-term downtrend and any bounce is likely a counter-trend move. Momentum is mixed: MACD histogram is slightly positive and expanding (0.0445), suggesting a minor rebound attempt, but RSI(6) ~46.5 is neutral and not signaling strong accumulation. Key levels: Pivot 21.609 is immediate “line in the sand.” Support: S1 21.157 then S2 20.877. Resistance: R1 22.062 then R2 22.342. A convincing long-term buy setup would typically require reclaiming and holding above ~22.06–22.34 with improving moving-average structure; that is not present now. Pattern-based probabilities also lean negative over 1w/1m (-1.02% next week, -2.59% next month).
Analyst Ratings and Price Target Trends
Recent analyst action: On 2026-01-08, Canaccord lowered the price target to $25 from $28 and maintained a Hold rating, citing an uncertain healthcare environment. Wall Street pros: stable earnings/revenue growth and a target still above current price. Cons: reduced confidence (PT cut), cautious sector/backdrop commentary, and the stock’s technical downtrend/insider selling weakens the bull case. No recent congress trading data available and no indication of politician/influential-figure trades in the provided data.
Wall Street analysts forecast HSTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSTM is 25 USD with a low forecast of 25 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast HSTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSTM is 25 USD with a low forecast of 25 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 21.740
Current: 21.740
